Compare VLY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | IBRX |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.2B |
| IPO Year | 1994 | 2015 |
| Metric | VLY | IBRX |
|---|---|---|
| Price | $13.79 | $6.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $17.04 | $14.25 |
| AVG Volume (30 Days) | 6.8M | ★ 12.0M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | ★ 46.38 | 38.71 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $12.61 | $99.98 |
| Revenue Next Year | $19.81 | $108.29 |
| P/E Ratio | $14.93 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $10.70 | $1.95 |
| 52 Week High | $15.20 | $12.43 |
| Indicator | VLY | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 36.40 |
| Support Level | $13.41 | N/A |
| Resistance Level | $13.96 | $8.62 |
| Average True Range (ATR) | 0.35 | 0.57 |
| MACD | -0.09 | -0.10 |
| Stochastic Oscillator | 2.56 | 10.19 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.